Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update

Steven M. Grunberg, David Osoba, Paul J. Hesketh, Richard J. Gralla, Sussanne Borjeson, Bernardo L. Rapoport, Andreas Du Bois, Maurizio Tonato

Research output: Contribution to journalReview articlepeer-review

159 Scopus citations


Development of effective antiemetic therapy depends upon an understanding of both the antiemetic agents and the emetogenic challenges these agents are designed to address. New potential antiemetic agents should be studied in an orderly manner, proceeding from phase I to phase II open-label trials and then to randomized double-blind phase III trials comparing new agents and regimens to best standard therapy. Use of placebos in place of antiemetic therapy against highly or moderately emetogenic chemotherapy is unacceptable. Nausea and vomiting should be evaluated separately and for both the acute and delayed periods. Defining the emetogenicity of new antineoplastic agents is a challenge, since such data are often not reliably recorded during early drug development. A four-level classification system is proposed for emetogenicity of intravenous antineoplastic agents. A separate four-level classification system for emetogenicity of oral antineoplastic agents, which are often given over an extended period of time, is also proposed.

Original languageEnglish (US)
Pages (from-to)80-84
Number of pages5
JournalSupportive Care in Cancer
Issue number2
StatePublished - Feb 2005
Externally publishedYes


  • Antiemetic
  • Classification
  • Emesis
  • Emetogenicity
  • Nausea

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update'. Together they form a unique fingerprint.

Cite this